Voyager Therapeutics
Yahoo Finance • 26 days ago
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological di... Full story
Yahoo Finance • 26 days ago
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Continue Reading... Full story
Yahoo Finance • last month
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
Quick Read Cramer blessed VYGR for a 23-year-old caller based purely on time horizon, not fundamentals, as the stock has dropped 69% over ten years. Analysts give VYGR 11 Buy ratings and a $15 average target, nearly four times the $3.50 p... Full story
- NVDA
Mentioned:
Yahoo Finance • 2 months ago
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., P... Full story
Yahoo Finance • 3 months ago
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Voyager Therapeutics Inc (NASDAQ:VYGR) is one of the best gene therapy stocks to buy in 2026. While the stock has risen only a modest 30% over the past year, analysts believe it can explode more than 250% over the next 12 months as the com... Full story
Yahoo Finance • 9 months ago
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Thera... Full story
Yahoo Finance • 9 months ago
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration -... Full story
Yahoo Finance • 10 months ago
Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders
Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story
Yahoo Finance • 11 months ago
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in... Full story
- MA
Mentioned:
Yahoo Finance • last year
Voyager Reports Second Quarter 2025 Financial and Operating Results
- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential... Full story
Yahoo Finance • last year
Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target
Investing.com - Baird maintained its Outperform rating and $18.00 price target on Voyager Therapeutics (NASDAQ:VYGR) stock following an in-person meeting with company management. According to InvestingPro data, the stock is currently tradi... Full story
Yahoo Finance • last year
Sector Update: Health Care Stocks Climb Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1.1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last year
Voyager Therapeutics unveils APOE-targeting Alzheimer's therapy program
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company whose stock has declined over 45% year-to-date according to InvestingPro data, on Wednesday announced a new gene therapy program targeting a... Full story
Yahoo Finance • last year
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise... Full story
Yahoo Finance • last year
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D.,... Full story
Yahoo Finance • last year
Voyager Reports First Quarter 2025 Financial and Operating Results
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 pr... Full story
Yahoo Finance • last year
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specific... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ: DAVE), Red Cat Holdings, Inc. (NASDAQ: RCAT), Pe... Full story
Yahoo Finance • last year
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523was well tolerated in healthy volunteers and sh... Full story
Yahoo Finance • last year
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and opera... Full story